摘要
摘要目的探讨低分子肝素联合阿托伐他汀对不稳定性心绞痛的治疗价值.方法根据WHO标准选取４６例不稳定性心绞痛患者为研究对象,分为治疗组与对照组(各２３例),对照组采用传统方法治疗,治疗组在传统治疗基础上,加用低分子肝素及阿托伐他汀,分别以心绞痛发作持续时间、频率、心电图等作为观测指标,共７天.结果治疗组心绞痛发作持续时间、频率、心电图等观测指标较对照组下降,经统计学分析,两组差异具有统计学意义(P＜０．０５).结论低分子肝素联合阿托伐他汀对不稳定心绞痛疗效显著,可改善患者预后,降低并发症.AbstractObjectiveToobservetheclinicaleffectofatorvastatincalciumandlowmolecularweightheparincalcicintreatingpatientswithunstableanginapectoris(UAP)．MethodsAccordingtoWHO,４６patientswerecollectedtobeobjectsofstudy,whichweredividedintotwogroup(２３patientseachgroup)．Twogroupsweretreatedwithcommonmethods,andthetreatmentgroupwasstillgivenatorvastatincalciumandlowmolecularweightheparincalcic．After７days,weagaindetectedtheseizurefrequency、durationofUAP,etc．ResultsAftertreatmentclinicfunctionindexesinthetreatmentgroupwereimprovedsignifＧicantlythanthecontrolgroup(P＜０．０５)．ConclusionAtorvastatincalciumandlowmolecularweightheparincalcicareeffectivedrugsintreatingpatientswithUKAeyPw．ordsAtorvastatincalcium;Lowmolecularweightheparincalcic;UAP中图分类号R５４１．４文献标识码B文章编号１００１－５３０２(２０１５)０９－０７９０－０２
出版日期
2015年09月19日（中国期刊网平台首次上网日期，不代表论文的发表时间）
